|
|
|
|
| Cygnal Technologies to provide metro area network for Apotex |
| Solution includes Nortel platform, Rogers network |
| November 10, 2005 |
MARKHAM, ONTARIO, November 10, 2005 – Cygnal Technologies Corp. (TSX: CYN) has been selected to provide a dedicated communications network connecting four Greater Toronto Area (GTA) locations of Apotex Inc., the largest Canadian-owned pharmaceutical company. The five year contract includes the implementation and maintenance of Nortel equipment and Rogers fibre to create a SONET metro area network, providing Apotex with dedicated bandwidth to more tightly integrate its major sites in the GTA.
“Cygnal has built 80% of the community networks in Ontario servicing the ‘MUSH sector’ – municipalities, universities, schools and hospitals,” said Todd Rutherford, President, Cygnal Network Solutions. “We are now applying this unique expertise to enterprise customers like Apotex who can realize tremendous benefits from connecting multiple sites through a scalable metro area network.”
After a period of rapid expansion during which it has completed major expansions to several sites, Apotex has found that some of its facilities require additional bandwidth to take full advantage of modern technologies.
“A reliable, high capacity, dedicated network will accommodate our growing need for real-time communications and information sharing among technical and research staff,” said William Shanks, Apotex Manager of Telecommunications and Network Services. “We were impressed by Cygnal’s experience in this area and their creativity in proposing solutions, and we look forward to working with them on this project.”
Cygnal will implement a metro area network built on Nortel’s Optera Metro 3500 platform, utilizing a combination of Apotex's existing fibre infrastructure and Rogers Cable’s fibre network to provide connectivity between the four sites. The solution is configured as an OC-48 (2.488 gigabit per second) SONET network, scalable to OC-192 (10 Gbps). Redundancy features will automatically reroute traffic in the event network degradation or failure are sensed. Cygnal’s ongoing support program will include network monitoring, remote and on-site diagnostics, repair and resolution.
About Apotex
Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its two employees, 5,000 square foot beginning, the company has grown to employ over 6,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies with 5,000 employees now occupy over 3.4 million square feet in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, Calgary and Vancouver. Apotex produces more than 260 generic pharmaceuticals in approximately 4000 dosages and formats which, in Canada, are used to fill over 60 million prescriptions a year - the largest amount of any pharmaceutical company in this country.
About Cygnal
Cygnal Technologies Corporation is a leading Canadian provider of network communication solutions including the design, installation, maintenance and management of wired and wireless communication networks. The Company offers a full range of technologies and solutions for service providers and enterprise customers. Cygnal has expertise in voice, video and data solutions over traditional and next generation converged technologies.
Cygnal Technologies Corporation is headquartered in Markham, Ontario and supports end-user customers and business partners through 14 offices across Canada, including Vancouver, Edmonton, Calgary, Winnipeg, London, Burlington, Brampton, Toronto, Sudbury, Ottawa, Montreal, Quebec City and Halifax. Cygnal common shares are listed on the Toronto Stock Exchange under the symbol CYN.
No stock exchange or regulatory authority has approved or disapproved of information contained herein. Certain information included in this news release is forward-looking and is subject to important risks and uncertainties. When used in this news release, the words "believe", "intend", "estimate", "expect", "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. These forward-looking statements are based on current expectations. The results or events predicted in these statements may differ materially from actual results or events. Factors which could cause results or events to differ from current expectations include, among other things, the impact of price and product competition, the ability of the Corporation to make acquisitions and/or integrate the operations and technologies of acquired businesses in an effective manner, general industry and market conditions and growth rates, the impact of consolidations in the telecommunications industry and stock market volatility. For additional information with respect to certain of these and other factors, see the reports filed by Cygnal Technologies with applicable Canadian securities administrators. Cygnal Technologies disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Todd Rutherford
President, Cygnal Network Solutions
Cygnal Technologies Corporation
905-944-6609
trutherford@cygnal.ca
Jeff Codispodi
Investor Relations
The Equicom Group Inc.
416-815-0700 ext. 261
jcodispodi@equicomgroup.com |
|
 |
